Tarlox and Sotorasib in Patients With KRAS G12C Mutations

NCT05313009 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

5

Enrollment

OTHER

Sponsor class

Stopped Study drug was discontinued by manufacturer for business reasons.

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG: Sotorasib and Tarloxotinib
DRUG: Sotorasib and Tarloxotinib

Sponsor

Medical University of South Carolina

Collaborators

[object Object]